Family Research Council calls for FDA transparency, honesty on "Emergency Contraceptive" Ella

This afternoon the Food and Drug Administration (FDA) Advisory Panel, considering the new "Emergency Contraceptive," Ella, which can also act as an abortifacient, voted against recommending ANY precautions or labeling that would inform women of the drug's abortifacient capabilities as well as health risks.

Jeanne Monahan, Family Research Council's Director of the Center for Human Dignity, released the following statement:

"The FDA is placing politics above science, women's health and informed consent. Family Research Council calls upon the Obama Administration and the FDA to make good on their promise of transparency and honesty. Women deserve to know that this drug can take a life that has already been implanted as well as the serious health risks it imposes, including infection and bleeding.  Women's health should not be jeopardized just to advance the agenda of the abortion industry."